Origin Biosciences, Inc.
Sentynl Therapeutics is a U.S.-based biopharmaceutical company focused on bringing innovative therapies to patients living with rare diseases. The company is committed to ethical standards and compliance, and aims to source effective and differentiated products across therapeutic areas to address unmet needs. It is dedicated to advancing treatments for rare diseases, including through partnerships and development programs.
Industries
Nr. of Employees
small (1-50)
Origin Biosciences, Inc.
Palo Alto, California, United States, North America
Products
Fosdenopterin (acquired product)
An investigational/existing substrate-replacement therapy that provides an exogenous cPMP source to restore molybdenum cofactor production for treatment of molybdenum cofactor deficiency Type A.
CUTX-101 (copper histidinate) product candidate
A subcutaneous injectable formulation of copper histidinate in development for treatment of Menkes disease; manufactured under cGMP and studied in pivotal clinical trials with reported survival and neurodevelopmental outcome benefits.
Lonafarnib (acquired product)
An oral therapy acquired for treatment of Hutchinson-Gilford Progeria Syndrome (progeria) as part of the company’s rare disease product portfolio.
Fosdenopterin (acquired product)
An investigational/existing substrate-replacement therapy that provides an exogenous cPMP source to restore molybdenum cofactor production for treatment of molybdenum cofactor deficiency Type A.
CUTX-101 (copper histidinate) product candidate
A subcutaneous injectable formulation of copper histidinate in development for treatment of Menkes disease; manufactured under cGMP and studied in pivotal clinical trials with reported survival and neurodevelopmental outcome benefits.
Lonafarnib (acquired product)
An oral therapy acquired for treatment of Hutchinson-Gilford Progeria Syndrome (progeria) as part of the company’s rare disease product portfolio.
Services
Licensing and asset acquisition
Identification, negotiation and execution of licensing or purchase agreements for late-stage development programs and marketed specialty products in the rare-disease space.
Expanded Access Protocol management
Administration of expanded access requests and conduct of a formal Expanded Access Protocol to provide investigational therapy to eligible patients and to collect supportive safety/efficacy data.
Patient access and support programs (Sentynl Cares)
Programs to facilitate patient access, reimbursement support and care navigation for children with rare diseases receiving company therapies.
Regulatory and commercialization support for partners
Services to support regulatory filings, approval strategy and commercialization planning for rare-disease products acquired or licensed to Sentynl.
Licensing and asset acquisition
Identification, negotiation and execution of licensing or purchase agreements for late-stage development programs and marketed specialty products in the rare-disease space.
Expanded Access Protocol management
Administration of expanded access requests and conduct of a formal Expanded Access Protocol to provide investigational therapy to eligible patients and to collect supportive safety/efficacy data.
Patient access and support programs (Sentynl Cares)
Programs to facilitate patient access, reimbursement support and care navigation for children with rare diseases receiving company therapies.
Regulatory and commercialization support for partners
Services to support regulatory filings, approval strategy and commercialization planning for rare-disease products acquired or licensed to Sentynl.
Expertise Areas
- Rare disease drug commercialization
- Clinical development and trial execution
- Regulatory submissions and global approvals
- Newborn screening and genomic diagnostics
Key Technologies
- Next-generation sequencing (NGS)
- Rapid whole-genome sequencing (rWGS)
- Whole-exome sequencing (WES)
- Newborn screening assay development